Akero Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Akero Therapeutics, Inc.
After a multi-year lull, NASH R&D has picked up this past year with key data readouts, several programs advancing toward Phase III and Madrigal's resmetirom under FDA review with a March 2024 action. This graphic provides a look at the overall status of NASH drug R&D.
The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out for.
The French biotech’s PPAR agonist has significantly reduced liver fat in non-alcoholic fatty liver patients with type 2 diabetes in a mid-stage trial, raising hopes for success in an ongoing pivotal program in non-alcoholic steatohepatitis.
Phase IIb data show that Akero’s efruxifermin on top of GLP-1 therapy is relatively safe and offers liver fat reductions and fibrosis improvements in NASH patients with type 2 diabetes.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.